Citations

Clear

201 citation(s) found for "Keller, FG".

Non–Prostate Cancer‐Related Factors That Influence Serum Prostate‐Specific Antigen: A Narrative Review of 45 Non‐Malignant PSA Modifiers
Stephan, Carsten , Jung, Klaus , Sutcliffe, Siobhan , Filella, Xavier , Phillips, Michael B. , Wolinsky, Howard , Ginsburg, Kevin , Keller, David K.

Mayo Clinic

The Prostate | November 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pros.70272 | PMID 43002634 Get It

ABSTRACT Background To consolidate into a single review more than forty non‐cancer‐related factors that have been found to elevate or reduce prostate‐specific antigen (PSA) levels in the peer‐reviewed literature, emphasizing their contribution to false‐positive and false‐negative clinical interpretations. Materials and Methods A narrative literature review was conducted using PubMed, focusing on human studies describing benign physiologic, infectious, inflammatory, iatrogenic, hormonal, pharmacologic, and laboratory‐related factors that influence PSA values. The review emphasizes contemporary studies but incorporates earlier foundational literature where relevant. Results Forty‐five non‐cancer‐related factors were identified that influence PSA values through biologic, mechanical, pharmacologic, or analytic mechanisms. Thirty factors were associated with transient or persistent PSA elevation, whereas fifteen were associated with PSA reduction. Some factors varied substantially in the strength, magnitude, and consistency of reported PSA effects across studies. PSA elevations were reported in association with prostatic inflammation or infection, urinary retention, ejaculation, non‐instrumental prostatic physical stimulation, urologic instrumentation, and systemic inflammatory conditions. PSA reductions were observed with medications including 5‐alpha‐reductase inhibitors, nonsteroidal anti‐inflammatory drugs, statins, thiazide diuretics, metformin, and certain lifestyle factors. Inter‐assay and inter‐laboratory variability alone has been reported to result in PSA differences exceeding 20%. Tables summarizing the approximate magnitude and duration of PSA change for each modifier were developed, along with a patient questionnaire intended to support, not replace, clinician judgment. Conclusion PSA interpretation must incorporate awareness of more than forty influencers that can alter PSA independent of any malignancy. Accounting for these PSA level‐altering variables can improve PSA test result specificity and enhance confidence in prostate cancer risk assessment. Use of a structured patient questionnaire, a thorough consideration of benign factors that can alter PSA, repeat testing when transient factors are present, and consistent blood assay methodology can reduce unnecessary imaging, unneeded biopsies, and missed malignancies.
Pivotal Clinical Trials on the Management of Diverticular Disease
Calabrese, Elisa C., Keller, Deborah S. , Calabrese, Elisa

Mayo Clinic

Clinics in Colon and Rectal Surgery | September 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2940-8050 Get It

Abstract The management of diverticular disease has undergone a major evolution over the past two decades, shifting away from episode-count triggers for surgery toward individualized strategies informed by patient-reported outcomes, recurrence risk, and high-quality randomized clinical trials. Pivotal decision analyses and randomized trials have reshaped the surgical treatment landscape, while parallel trials of antibiotic therapy have transformed the nonoperative management of uncomplicated disease. In this study, we provide a comprehensive synthesis of historical perspectives and modern evidence regarding the surgical and nonoperative management of diverticulitis, summarize key randomized trials across the disease spectrum, describe the evolution of operative techniques, and translate these findings into actionable guidance, including a patient-centered decision aid. A structured narrative review of pivotal trials, major guidelines, and multicenter randomized studies were performed, encompassing trials of antibiotic therapy for uncomplicated diverticulitis, laparoscopic lavage for perforated disease, operative strategy for complicated disease, elective resection versus conservative therapy for recurrent or persistent symptoms, and the evolution of minimally invasive and robotic surgical techniques. Trial design, eligibility, interventions, outcomes, and limitations were extracted and synthesized. The traditional “two-episode rule” has been supplanted by individualized, symptom- and quality of life (QoL)-driven decision-making. Routine antibiotic therapy for uncomplicated diverticulitis is not supported by randomized evidence and is now reserved for select patients. Laparoscopic lavage, initially promising for perforated diverticulitis, demonstrates variable outcomes and is now reserved for selected patients with Hinchey III disease; when resection is required, primary anastomosis with diverting ileostomy is increasingly favored over Hartmann's procedure because of markedly higher stoma reversal rates. Randomized trials of elective sigmoid resection show reduced recurrence and improved QoL for patients with persistent symptoms, though not universally across all patient groups, and minimally invasive-particularly robotic-surgical techniques continue to reduce perioperative morbidity. Contemporary management of diverticulitis requires individualized evaluation anchored in patient-reported outcomes, disease phenotype, comorbidity, and shared decision-making. This study synthesizes the current evidence and provides clinic-ready decision aid for patient discussions.
Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials
Renfro, Lindsay A., Wu, Yue, Marcotte, Erin, Trippett, T, Horton, Terzah, Keller, Frank G., Forlenza, Chris, Schwartz, Cindy, Kelly, Kara M., Cole, Peter D., Castellino, Sharon M., Kahn, Justine M., Marcotte, Erin L. , Heneghan, Mallorie B. , Crisler, Katia M. , Trippett, Tanya, Horton, Terzah M. , Hoppe, Bradford S. , Keller, Frank G. , Schwartz, Cindy L. , Kelly, Kara M. , Castellino, Sharon M. , Kahn, Justine M

Mayo Clinic

Pediatric Blood & Cancer | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/1545-5017.70522 | PMID 42496647 Get It

ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and Hispanic (vs. non‐Hispanic White [NHW]) patients experienced higher post‐relapse mortality. It is unknown whether post‐relapse disparities persist when second‐line treatment is delivered in a cooperative group trial setting. We examined overall survival (OS) by race and ethnicity in CAYAs enrolled in COG trials for relapsed/refractory (r/r) cHL. Methods A pooled analysis of individual‐level data from CAYAs (≤ 29 years) receiving therapy for r/r cHL on COG clinical trials (2001–2016) was conducted. The Kaplan–Meier method estimated 3‐year OS by racial and ethnic groups. Cox regression models examined associations of race and ethnicity and OS, adjusted for age, insurance, first versus ≥2 relapse, and time from initial diagnosis to relapse trial enrollment. Results Among 175 CAYAs treated on COG trials for r/r cHL (5.7% Asian or Pacific Islander, 14.9% Hispanic, 14.3% NHB, 61.7% NHW, 3.4% other), at median follow‐up of 4.9 years, 3‐year OS was 82.1% (95% confidence interval [CI], 75.3%–87.1%) and did not differ by race and ethnicity ( p = 0.36). In multivariable analyses, shorter time from diagnosis to relapse trial enrollment ( p = 0.01) and ≥2 relapses (vs. first, p = 0.004) conferred worse OS, with no significant effect of race and ethnicity ( p = 0.43). Conclusion Post‐relapse survival did not differ by race and ethnicity among CAYAs enrolled in COG trials for r/r cHL, suggesting access to clinical trials may mitigate OS disparities.
Guidelines for rigor and reproducibility of heart rate variability within human cardiovascular research
Jenkins, Nathaniel D.M. , Bigalke, Jeremy A. , Robinson, Austin T. , Keller‐Ross, Manda L. , Greaney, Jody L. , Fonkoue, Ida T. , Fadel, Paul J. , Macefield, Vaughan G. , Charkoudian, Nisha , Carter, Jason R , Jenkins, Nathaniel D M , Bigalke, Jeremy A , Robinson, Austin T , Keller-Ross, Manda , Greaney, Jody L , Fonkoue, Ida T , Fadel, Paul J , Macefield, Vaughan G , Charkoudian, Nisha , Levine, Benjamin D , Joyner, Michael J , Carter, Jason R. , Levine, Benjamin D. , Joyner, Michael J.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1152/ajpheart.00041.2026 | PMID 42495990 Get It

Heart rate variability (HRV) is a widely utilized approach for investigating cardiovascular health and human performance. Methodological approaches, analyses, and interpretations of HRV can vary extensively, and scientific debates on HRV reliability and utility remain. These debates have been amplified in recent years by the rapid growth and ubiquity of wearable devices, and their incorporation into scientific research studies. The present guidelines paper takes an evidence-based approach to propose more consistent and rigorous measurement and interpretation of HRV within human cardiovascular research and application. First, HRV has some utility as a cardiovascular risk stratification tool, but is not appropriate to employ as a specific marker of cardiac sympathetic outflow or sympathovagal balance. While time-domain and spectral analysis can more accurately reflect respiratory modulation of cardiac vagal (parasympathetic) activity, caution is necessary to avoid overinterpretation, particularly with respect to the concept of “vagal tone”. Numerous experimental, demographic, and environmental factors influence HRV assessment, interpretation, and reliability. Specifically, it is critical to account for non-modifiable (age, sex, race/ethnicity, etc.) and modifiable (i.e., exercise, physical fitness, etc.) factors within participant samples. Furthermore, technical approaches such as the HRV input signal (e.g., electrocardiography vs. photoplethysmography), length of recording, location of recordings (i.e., laboratory vs. field), respiratory rate and depth, and analytical approaches (i.e., time vs. frequency domain) can all impact rigor, reliability, and study interpretations. Finally, with respect to the rapid advancements of HRV assessment using wearable technology, investigators should interpret and contextualize findings within the limitations outlined in this guideline review.
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331
Casey, Dana L. , Renfro, Lindsay A., Wu, Yue , McCarten, Kathleen, Pei, Qinglin , Milgrom, Sarah A., Cho, Steve, Keller, Frank G., Punnett, Angela, Kelly, Kara M., Castellino, Sharon M., Hoppe, Bradford S , Casey, Dana L , McCarten, Kathleen M. , Belsky, Jennifer A. , Keller, Frank G. , Punnett, Angela , Hodgson, David , Hoppe, Bradford S. , Kelly, Kara M. , Castellino, Sharon M.

Mayo Clinic

British Journal of Haematology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70625 | PMID 42419755 Get It

Summary Outcomes for high‐risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra‐nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2–21 years with high‐risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE‐PC) versus Bv‐AVEPC. Patients with stage IV disease, determined by protocol‐defined and centrally reviewed Positron Emission Tomography ‐ Computed Tomography (PET‐CT), were identified. Baseline characteristics and progression‐free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE‐PC and 167 (49%) Bv‐AVEPC. PFS was highest with lung‐only involvement (4‐year PFS 88.6%) and lowest with bone marrow‐only involvement (4‐year PFS 71.9%). Compared to ABVE‐PC, Bv‐AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33–0.85) and in the lung‐only and bone‐only subgroups. However, no PFS benefit was observed in those with bone marrow‐only involvement. Among paediatric patients with stage IV cHL, Bv‐AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone, Lena E. , Logan, Brent R. , Liu, Xuerong , Williams, Olatundun , Dunn, Elizabeth A. , Thakar, Monica S. , Kidd, Sharon A. , Dorsey, Morna J. , O'Reilly, R, Kapoor, Neena , Kapadia, Malika , Jyonouchi, Soma , Chandra, Sharat , Chellapandian, Deepak , Chaudhury, Sonali , Chen, Karin , Rayes, Ahmad , Quigg, Troy C. , Teira, Pierre , Gillio, Alfred P. , Eissa, Hesham, Knutsen, Alan P., Aquino, Victor M. , Shereck, Evan , Lugt, Mark T. Vander , Rozmus, Jacob, Yu, Lolie C. , Shah, Ami J. , Joshi, Avni Y. , Buckley, Rebecca H. , Oved, Joseph H. , Azim, Hisham Abdel, Martinez, Caridad , Sullivan, Kathleen E. , Bleesing, Jack J., Madden, Lisa, Shenoy, Shalini , Seroogy, Christine M. , Rubin, Tamar N. , Licata, Jennifer, Andolina, Jeffrey R. , Burroughs, Lauri M. , Leiding, Jennifer W. , Marsh, Rebecca , Pai, Sung‐Yun , Torgerson, Troy R. , Heimall, Jennifer , Griffith, Linda M. , Puck, Jennifer M. , Dvorak, Christopher C. , Cowan, Morton J. , Liu, Xuerong , Mousallem, Talal , Dorsey, Morna J , O'Reilly, Richard J , Kapoor, Neena , Forbes Satter, Lisa R , Kapadia, Malika , Chandra, Sharat , Ebens, Christen L , Chellapandian, Deepakbabu , Chaudhury, Sonali , Chen, Karin , Dávila Saldaña, Blachy J , Rayes, Ahmad , Quigg, Troy C , Chandrakasan, Shanmuganathan , Bednarski, Jeffrey J , DeSantes, Kenneth B , Teira, Pierre , Gillio, Alfred P , Eissa, Hesham , Aquino, Victor M , Shereck, Evan B , Moore, Theodore Bruce , Caywood, Emi H , Vander Lugt, Mark T , Rozmus, Jacob , Broglie, Larisa A , Yu, Lolie C. , Shah, Ami J , Joshi, Avni Y , Buckley, Rebecca H , Dara, Jasmeen , Oved, Joseph H , Abdel Azim, Hisham , Martinez, Caridad , Prockop, Susan E , Sullivan, Kathleen E , Bleesing, Jack J , Keller, Michael D , Madden, Lisa M , Parikh, Suhag , Shenoy, Shalini , Seroogy, Christine M , Rubin, Tamar , Licata, Jennifer , Andolina, Jeffrey R , Kohn, Donald B , Burroughs, Lauri M , Leiding, Jennifer W , Marsh, Rebecca A , Notarangelo, Luigi D , Pai, Sung-Yun , Torgerson, Troy R , Pulsipher, Michael A. , Heimall, Jennifer , Cuvelier, Geoffrey D E , Griffith, Linda M , Puck, Jennifer M , Dvorak, Christopher C , Cowan, Morton J , Haddad, Elie , Winestone, Lena E , Satter, Lisa Forbes , Ebens, Christen L. , Saldaña, Blachy J. Dávila , Chandrakasan, Shanmuganathan , Knutsen, Alan P. , Broglie, Larisa , Dara, Jasmeen , Abdel‐Azim, Hisham , Prockop, Susan E. , Bleesing, Jack , Keller, Michael D. , Parikh, Suhag , Kohn, Donald B. , Cuvelier, Geoff D.E. , Haddad, Élie

Mayo Clinic

Journal of Human Immunity | July 7, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20250231 | PMID 42416786 Get It

Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
A75-20 Analysis of Data From a Prospective Medicare Approved Clinical Trial Registry Indicates That Use of Maintenance Extracorporeal Photopheresis Is Independently Associated With Enhanced Survival of Lung Allograft Recipients Who Have Developed Life-Thre
Despotis, G J, Hachem, R R, Hage, C A, Walia, R, Goldberg, H J, Patel, M, Reynolds, J M, Klesney-Tait, J, Arcasoy, S M, Naik, C, Simone, N De, Usmani, A, Girgis, R E, Cordova, F C, Keller, B C, Nunley, D R, Javanbakht, A, Patil, J M, Morrell, M R, Lendermon, E A, Huang, H J, Pelaez, A, Emtiazjoo, A, Wille, K M, Chan, K M, Yung, G, Baz, M A, Aryal, S, Banez-Sese, G, Vedantham, S, Derfler, C, Commean, P, Berman, K, Atkinson, A, Atkinson, J J, Prokudin, A, Betensley, A D, Byers, D E, Despotis, G. J., Hachem, Ramsey R. , Hage, C A, Walia, Rajat , Reynolds, J.M., Klesney‐Tait, Julia , Arcasoy, S M, Naik, C., Girgis, Reda E. , Cordova, F C, Keller, Brian C. , Nunley, D R, Patil, Jagadish , Morrell, M R, Lendermon, Elizabeth A. , Huang, H J, Emtiazjoo, A.M., Wille, Keith , Chan, K.M., Yung, G, Baz, Maher A. , Aryal, S, Banez‐Sese, Grace, Vedantham, Suresh , Berman, Keith, Prokudin, A, Betensley, Alan D. , Byers, Derek E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.333 Get It

Abstract Rationale This Registry was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to arrest the rate of FEV1 decline (FEV1 decline) and prolong survival in lung allograft recipients with Bronchiolitis Obliterans refractory to standard of care therapy. Methods After IRB approval, 258 lung transplant recipients were enrolled from 20 US lung transplant centers. Subjects were assigned to ECP treatment (ECPRx) (i.e., 24 procedures over 6 months) at or a few months after enrollment based on spirometric criteria. Maintenance ECPRx (mECP) was at the discretion of managing clinicians. Rate of FEV1 decline in mL/month (FEV1 decline) was compared between 6 months prior to and 6 & 12 months after ECPRx initiation using linear mixed effects models. Time 0 for survival was set as the start of ECPRx for generation of Kaplan-Meier curves. Hazard Ratios (HR) with 95% confidence intervals (lower-upper) were generated using Cox Proportional Hazards Regression to characterize significant (p < 0.05) independent associations of mECP and/or any other covariates (i.e., demographic, operative, enrollment site, spirometric ) and survival. Results An 89% (78%-96%) decrease in the FEV1 decline was observed 12 months after ECPRx initiation in 191 participants assigned to ECPRx. FEV1 decline (-164 mL/month: 144-185) was greater (p < 0.001) in participants who expired within six months of Time 0 (n = 28) vs participants (-111 mL/month: 101-120) who died six months after Time 0 (n = 77). Of 159 participants who survived for at least six months after ECPRx initiation, 40 participants without mECP, who had up to 24 ECPRx (ECPRx: n = 19), had a lower survival HR: 2.43(1.75-3.4) (p < 0.001) relative to 119 participants who received mECP (ECPRx: n = 86)(see Figure). The response to ECPRx (% Change in FEV1 decline prior to and 6 months after 1st ECP) was similar between subcohorts (No mECP: -81 decrease vs mECP: -85%, p = 0.3). The association of mECP persisted after multivariate adjustment HR 1.8 (1.8-2.7)(p = 0.002) using significant covariates: FEV1 HR 0.37 (0.3-0.5), FEV1 decline HR 0.001 (0.001-0.04), Male Gender HR 2.4 (1.7-3.4); Reflux Disease HR 1.8 (1.2-2.8); Coronary Disease HR 1.8 (1.2-2.7). Conclusions This analysis indicates that mECP is independently associated with enhanced survival most likely due to attenuation of relapse six months after ECP initiation based on similar initial response to ECPRx. A risk-adjusted, control cohort is being pursued to facilitate submission of a scientifically rigorous petition to CMS to expand the ECP National Coverage Decision to include BOS predicated on CMS 2024 scientific guidelines. This abstract is funded by: Therakos Inc
Advances and Controversies in the Management of Diverticulitis
Keller, Deborah, Keller, Deborah

Mayo Clinic

Clinics in Colon and Rectal Surgery | May 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2872-9082 Get It

SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Uprety, Anusha , Judd, Chandler , Villella, Emily D , Keller, Rebecca , Wagner, Ryan, Robertson, Keith D. , Rodríguez‐Blanco, Jezabel , Barnoud, Thibaut , Mason, Frank M. , Ho, Thai H. , Wagner, Ryan T , de Cubas, Aguirre A , Ho, Thai , Robertson, Keith D , Wagner, Ryan T.

Mayo Clinic

Cancer Research | April 30, 2026 | Volume: 86 | Issue: 15 | Pages: 3838-3852

10.1158/0008-5472.can-25-3195 | PMID 42060867 Get It

Abstract SETD2 is frequently mutated or deleted in clear cell renal cell carcinoma (ccRCC). Loss of SETD2 could create synthetic lethal dependencies that confer therapeutic vulnerabilities. In this study, we demonstrated that SETD2 deficiency promotes cytoplasmic mitochondrial DNA (mtDNA) leakage, leading to basal activation of cGAS-STING inflammatory signaling and increased apoptotic priming. This inflammatory state upregulated the BH3-only protein NOXA, constrained myeloid cell leukemia 1 (MCL-1) function, and enforced a synthetic lethal dependency on the antiapoptotic protein BCL-xL. Pharmacologic inhibition of BCL-xL further amplified cGAS-STING signaling in SETD2-deficient cells through sublethal mitochondrial outer membrane permeabilization, resulting in increased mtDNA release and robust NOXA induction. Elevated NOXA neutralized the compensatory MCL-1–mediated survival signaling, triggering apoptosis. In contrast, SETD2-proficient ccRCC cells exhibited minimal cGAS-STING activation and failed to induce NOXA following BCL-xL inhibition, rendering them resistant. Genetic ablation of cGAS, STING, IRF3, or NOXA rescued sensitivity to BCL-xL inhibition, confirming that mtDNA-driven innate immune signaling is required for this dependency. In vivo, BCL-xL inhibition suppressed tumor growth and prolonged survival in SETD2-deficient xenograft models. Collectively, these findings establish a mechanistic link between SETD2 loss, mtDNA-driven innate immune activation, and enforced BCL-xL dependence in ccRCC, revealing a therapeutically targetable vulnerability in SETD2-deficient tumors. Significance: SETD2 deficiency, which is associated with worse prognosis in kidney cancer, promotes mitochondrial DNA-driven cGAS-STING signaling and NOXA-mediated apoptotic priming, creating a therapeutically targetable dependency on BCL-xL in kidney cancer.
Management of outpatient parenteral antibiotic therapy: a United States-based multi-center survey
Castellino, Laila M , Rivera, Christina G. , Beekmann, Susan E. , Mahoney, Monica V. , Keller, Sara C. , Mahoney, Monica V , Keller, Sara C , Rivera, Christina G , Beekmann, Susan E , Polgreen, Philip M.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | April 17, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2026.10347 | PMID 42038603 Get It

Abstract Objective: Outpatient parenteral antimicrobial therapy (OPAT) programs continue to evolve with increases in multidisciplinary teams, complex oral antibiotics, long-acting injectable antimicrobials, patients with substance use disorder (SUD) and telehealth. We sought to examine how OPAT programs are currently structured and identify barriers to safe care. Design: Cross-sectional survey. Participants: Physician, pharmacist, and advanced practice providers (APP) Emerging Infections Network (EIN) members. Methods: A survey was conducted between February and March 2025 to assess OPAT structure, expansion to complex outpatient antimicrobial therapy (COpAT), and barriers to safe OPAT care. Results: Of 1639 EIN members, 622 (38%) responded; 75% reported an active role in OPAT. Oversight of patients on COpAT was reported by 59%, and mandatory ID consultation for OPAT by 59%. Eighty-one percent reported >75% of OPAT patients were followed by ID. Most patients received OPAT at home (78%) followed by post-acute care facilities. Outpatient and inpatient ID physicians were responsible for laboratory test monitoring (75% and 30% respectively), while 37% reported a multidisciplinary OPAT team and 32% reported non-specialists. Respondents cited inadequate support in data analysis, administration, information technology and financial support for clinical staff. Common challenges were lack of leadership awareness (51%), difficulty managing patients with SUD (50%) and timely access to laboratory test results (48%). Conclusions: ID physicians were commonly involved in OPAT care, with many programs expanding to COpAT. Several barriers to the safe delivery of OPAT remain, including lack of institutional support, reimbursement and poor communication between stakeholders.